問卷

TPIDB > Principal Investigator

Principal Investigator


Koo Foundation Sun Yat-Sen Cancer Center (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of Others-

China Medical University Hospital

Division of Hematology & Oncology

更新時間:2023-09-19

鄭小湘
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

73Cases

2022-03-01 - 2028-04-30

Phase III

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)
  • Condition/Disease

    Metastatic Non Small Cell Lung Cancer

  • Test Drug

    datopotamab deruxtecan (Dato-DXd; INN: DS-1062a)

Participate Sites
9Sites

Recruiting9Sites

2023-03-06 - 2030-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-11-01 - 2030-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites